

Potential Effects of Polyphenols on Osteoblast and Osteoclast Culture

Nurul Husna Azizul¹, Hermizi Hapidin^{1,*}, Hasmah Abdullah¹, Maryam Azlan¹, Azlina Ahmad², Ima Nirwana Soelaiman³



Use your smartphone to scan this QR code and download this article

¹Biomedicine Programme, School of Health Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia

²School of Dental Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia

³Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia

Correspondence

Hermizi Hapidin, Biomedicine Programme, School of Health Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia

Email: hermizi@usm.my

History

- Received: Oct 13, 2022
- Accepted: Jan 11, 2023
- Published: Jan 31, 2023

DOI : 10.15419/bmrat.v10i1.786



Copyright

© Biomedpress. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.



ABSTRACT

Bone tissue undergoes constant remodeling by reducing the accumulation of bone damage and retaining the mechanical strength of bones to sustain both structural integrity and bone density. There are two main specialized cells involved in the bone-remodeling process, osteoblasts (OBs) and osteoclasts (OCs), which are responsible for new bone formation and aged bone resorption, respectively. The proper balancing act between bone resorption by OCs and bone deposition by OBs is essential for the active and dynamic process of bone remodeling. Polyphenols are a group of phytochemicals that are found in plants. Due to their bioactive components, like flavonoids, phenolic acids, and stilbenes, medicinal plants have long been pursued in the drug development process. Many medicinal plant extracts have been found to improve bone health. To provide more applicable preclinical research results, scientists have concentrated on developing *in vitro* models of bone cells by utilizing cell lines or primary cells. However, OBs and OCs do not act independently of one another, and various communication pathways between them have been discovered. This review summarizes the relevant data from existing studies on the effects of polyphenols on OBs and OCs using monocultures; these studies can be further enriched using co-culture, which represents an experimental system closer to the *in vivo* conditions than monoculture, allowing realistic cell-cell interactions. This information will be valuable for the development of new pharmaceutical and nutraceutical agents to treat and manage bone diseases.

Key words: Osteoblast, Osteoclast, Polyphenol, Bone remodeling

INTRODUCTION

Bone remodeling is the dynamic process of bone formation and resorption in vertebrates to maintain bone volume and calcium homeostasis^{1,2}. Osteoclasts (OCs) and osteoblast (OBs) are the two main specialized cells involved in the bone remodeling process through which the old or damaged bones are resorbed by OCs (bone resorption) and new bone is formed by OBs (bone formation)^{3,4}. The proper balancing act between bone resorption by OCs and bone deposition by OBs is important in the maintenance of healthy bones^{2,4}.

OBs and OCs work in balance, and a dysregulated interplay or imbalance between these cell types may result in implications on the bone that vary from fractures that do not heal effectively to major conditions, such as osteoporosis or in rare cases, osteopetrosis⁵⁻⁸. The National Institutes of Health Consensus Development Panel defines osteoporosis as “a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture”^{9,10}. Osteoporosis is a silent disease that is often undiagnosed^{11,12}. Before the patient experiences a fracture

at a significant bone location, such as the hip, spine, proximal humerus, pelvis, and/or wrist, with or without trauma, it remains asymptomatic until further diagnosis and treatment^{11,12}.

As the population ages, osteoporosis will become more prevalent and will have a greater influence on clinical, economic, and social outcomes for people of all sexes and ethnicities^{11,13}. The treatment cost of a hip fracture in developing countries, like Malaysia, is expected to increase from 35.3 million USD in 2018 to 125.4 million USD in 2050¹³. Increasing age, female sex, postmenopausal status, hypogonadism or premature ovarian failure, low body mass index, ethnic background, rheumatoid arthritis, low bone mineral density (BMD), vitamin D deficiency, low calcium intake, hyperkyphosis, smoking, alcohol abuse, immobilization, and long-term use of certain medications are a few of the factors that can cause osteoporosis¹⁴.

Antiresorptive and anabolic therapies have been established for the treatment of osteoporosis using numerous drugs and biomaterials with the aim of activating bone formation or suppressing OC function

Cite this article : Azizul N H, Hapidin H, Abdullah H, Azlan M, Ahmad A, Soelaiman I N. **Potential Effects of Polyphenols on Osteoblast and Osteoclast Culture.** *Biomed. Res. Ther.*; 2023, 10(1):5476-5490.

and survival¹⁵. To provide more applicable preclinical research results, scientists have concentrated on developing *in vitro* models of bone cells utilizing cell lines or primary cells¹⁶. Studies have been conducted on primary cells, such as primary mouse mesenchymal progenitor cell-derived OBs^{17,18}, primary human osteoblast (Hob) cells, and PMBC-derived OCs¹⁹. Cell lines include the human fetal osteoblast cell line (hFOB 1.19)²⁰, RAW264.7-derived OCs²¹, and MC3T3-E1 OBs²². Because OBs and OCs are important during osteogenesis and remodeling, these cells are used for *in vitro* studies of bone diseases^{23,24}. These cells do not behave independently of one another, and various communication pathways between them have been discovered²⁴.


Therefore, the complex interactions of OBs and OCs and their precursors during bone remodeling are best studied and understood using co-culture, which may provide more information on the engineering of bone tissues²⁵. The monoculture model involves only one cell type in a culture medium, whereas the co-culture method includes multiple cell types, which are cultured together in the same medium. This review summarizes the effects of polyphenols on both OBs and OCs using a monoculture model. Further research on polyphenols should be conducted with the development of a co-culture model as it allows for optimal cell-cell interactions and mimics the *in vivo* environment more accurately than a monoculture²⁶.

POLYPHENOLS

The class of phytochemicals known as polyphenols is present in a variety of plants, including apples, berries, citrus fruit, plums, broccoli, chocolate, tea, and coffees^{27,28}. Phenols (hydroxybenzenes), especially polyphenols (containing two or more phenol groups), are synthesized by plants; they perform important roles under certain difficult conditions, such as when pathogens are present or when the climate is challenging^{28,29}. Polyphenols can be divided into four significant groups determined by the number and binding structure of the phenol units: flavonoids, stilbenes, lignans, and phenolic acids (Figure 1)^{30,31}.

Flavonoids

Flavonoids can be found in edible plants, such as cranberries (*Vaccinium macrocarpon*) and apples (*Malus sylvestris*). They are present as O-glycosides with sugars, such as glucose and/or rhamnose, linked to the phenolic hydroxyl groups or directly bonded to the carbon skeleton³². Flavonoids can also exist as polymers or aglycons in the seeds of plants³². Anthocyanins, flavanols, flavanones, flavones, flavonols and



isoflavonoids are the main classes of flavonoids³³. **Table 1** summarizes the effects of flavonoids on OBs and OCs based on previous studies conducted using the *in vitro* monoculture model.

Table 1: Effects of polyphenols on OBs and OCs

Polyphenols	Bioactive compound	Effects on OBs	Effects on OCs
Flavonoids	(2S,3S)- Aromadendrin-6-C- β -D-glucopyranoside (AG) from the ex- tract of <i>U. wallichiana</i> (Himalayan Elm).	Swarnkar <i>et al.</i>, (2011): - increased differentiation of preOBs obtained from neonatal mouse calvaria. - elevated gene expression of osteogenic markers, Runx2, Bmp2, Col1, and Bglap in preOBs. - increased extracellular matrix mineralization in preOBs and bone marrow cells. - protected the differentiated OBs from serum deprivation-induced apoptosis.	Swarnkar <i>et al.</i>, (2011): - increased the expression of the anti-osteoclastogenic cytokine, Tnfrsf11b. - inhibit OCs differentiation of bone marrow precursor cells to OCs in the presence of RANKL and M-CSF.
	Kaempferol [3,5,7- trihydroxy-2-(4- hydroxyphenyl)-4 H-1- benzopyran-4-one]	Tsuchiya <i>et al.</i>, (2018): - increased Alpl activity and calcium deposition. - increase Runx2, Bglap, Sparc, Spp1 Guo <i>et al.</i>, (2012): - activated the transcriptional activity of pERE-Luc and induced estrogen receptor α (ER α) phosphorylation that was correlated with induction and associated with OBs differentiation biomarkers. - promoted the mineralization process of OBs.	Kim <i>et al.</i>, (2018): - reduced TRAP-positive cells and resorption pits. - reduced RANKL, TRAF6, c-Fos, NFATc1. - reduced p-ERK and p-JNK. - reduced beclin-1 and SQSTM1/p62 Wattel <i>et al.</i>, (2003): - reduced bone resorption in dose and time dependent manner. - directly induced apoptosis of mature OCs in same dose-range effective for inhibiting bone resorption.
	Luteolin (3',4',5,7- tetrahydroxyflavone)	Melguizo-Rodríguez <i>et al.</i>, (2019): - elevate the expression of Runx2, Alpl, Col1, Sp7 and Bglap, Choi, (2007): - increased collagen content, ALP activity, and <i>Bglap</i> secretion.	Craсто <i>et al.</i>, (2013): - produced deeper resorption pits, but with decreased surface area, resulting in overall decreased pit volume. - disruption of OCs V-ATPase <i>a3-d2</i> interaction.

Continued on next page

Table 1 continued

Polyphenols	Bioactive compound	Effects on OBs	Effects on OCs
Stilbenes	Piceatannol (3,3',4,5'-tetrahydroxy-trans-stilbene)	<p>Chang et al., (2006):</p> <ul style="list-style-type: none"> - increased alkaline phosphatase activity and mRNA expression in a dose-dependent manner. - increased the levels of Bglap protein. - increased Col1 protein levels. - increased the amount of OBs mineralization in a dose-dependent manner. 	<p>Yan et al., (2019):</p> <ul style="list-style-type: none"> - attenuated RANKL-induced OC differentiation. - inhibited OC-mediated bone resorption. - inhibited RANKL-stimulated OC-specific gene expression. - suppressed RANKL-stimulated activation of NF-κB, JNK, ERK and AKT. - promoted caspase 3-mediated apoptosis of mature OCs.
Lignan	Gastrodin	<p>Liu et al., (2018):</p> <ul style="list-style-type: none"> - increased mRNA levels of osteogenic genes (Runx2, OSX, Bmp2 and Bglap). - increased Alpl activity and calcium deposit 	<p>Zhou et al., (2017):</p> <ul style="list-style-type: none"> - inhibited RANKL-induced OCs differentiation by downregulating the expression of NFATc1. - inhibited gene expression of Dcstamp thus preventing OCs maturation and migration. - prevented RANKL induced-osteoclastic bone erosion.
Phenolic acid	Tannic acid	<p>Hapidin et al., (2019):</p> <ul style="list-style-type: none"> - increased proliferation by increasing OBs cell number. - OBs morphology was uniformly fusiform shaped with filopodia extensions. - improved mineralization by increasing the percentage of Ca and P. 	<p>Steffi et al., (2019):</p> <ul style="list-style-type: none"> - reduced TRAP activity and OCs cell number.
	3-(3-hydroxyphenyl) propionic acid	<p>Chen et al., (2016):</p> <ul style="list-style-type: none"> - stimulated OBs cell differentiation. - increased OBs cell differentiation markers (<i>Col1</i> and <i>Spp1</i>). 	<p>Zhao et al., (2019):</p> <ul style="list-style-type: none"> - inhibited osteoclastogenesis through a RANKL-RANK independent mechanism. - reduced osteoclastogenesis and OCs resorptive activity in dose-dependent manner. - inhibited NFATc1 expression, with a subsequent reduction in expression of downstream osteoclastogenic marker genes.

(2S,3S)-aromadendrin-6-C- β -D-glucopyranoside (AG) is a flavonoid isolated from the stem bark of *Ulmus wallichiana*³⁴. Swarnkar *et al.* (2011) found that AG treatment significantly increased the differentiation and expression of mineralization markers on OBs isolated from the calvaria of 1–2-day-old Balb/c mice. AG treatment for 21 days produced a 40% increase in mineralization (Alizarin red staining) compared with a control at 100 nM (10^{-7} M)³⁴. In addition, 48-h treatment with AG increased alkaline phosphatase (Alpl) production by 80% over control at 100 nM³⁴. Furthermore, 24-h treatment increased mRNA levels of runt-related transcription factor 2 (*Runx2*), and 48-h treatment increased bone morphogenetic protein 2 (*Bmp2*), collagen type-1 (*Col1*), and osteocalcin (*Bglap*), which are important osteogenic gene expression markers³⁴.

In addition to the increase in OB differentiation, AG subsequently increased osteoprotegerin (*Tnfrsf11b*) levels after 24 h and 48 h of treatment³⁴. *Tnfrsf11b* is a soluble decoy receptor for the nuclear factor- κ B ligand receptor activator, which is essential for the differentiation of OCs³⁵. In contrast, AG directly inhibited OC differentiation by blocking RANKL+ macrophage colony stimulating factor 1 (M-CSF-1)-induced osteoclastogenesis in murine bone marrow cells, as evidenced by reduced expression of OC phenotypic markers. In addition, treatment with 100 nM AG on day 6 decreased mRNA levels of tartrate-resistant acid phosphatase (TRAP), c-fos, RANK, and cathepsin K (*Ctsk*)³⁴.

Kaempferol [3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4 H-1-benzopyran-4-one] is a natural flavonoid with a low molecular weight that is present in foods like broccoli, cabbage, beans, tomatoes, strawberries, grapes, and tea³⁶. Previous studies have shown that kaempferol exhibits antioxidant and anticancer activities *in vitro* and *in vivo*³⁶. Furthermore, it can be applied to the management of osteoporosis. Wattel *et al.* (2003) reported that kaempferol significantly reduced bone resorption by promoting spontaneous OC apoptosis³⁷. OCs were obtained and purified from unfractionated bone cells from long bones of 10-day-old rabbits and were cultured for 48 h before treatment with kaempferol³⁸. Treatment with 50 μ M kaempferol increased the number of apoptotic OCs compared with a control. Another study on murine macrophage RAW264.7 cells treated with RANKL for 9 days reported that treatment with 50 μ M kaempferol inhibited RANKL-induced differentiation of RAW 264.7 cells³⁹. In addition, the treatment inhibited the activation of extracellular signal-regulated kinase (ERK)

and c-Jun N-terminal kinase (JNK) of the mitogen-activated protein kinase (MAPK) pathway, which subsequently reduced the expression of RANKL, TNF receptor-associated factor 6 (TRAF6), c-Fos, and NFATc1. Furthermore, kaempferol treatment suppressed OC autophagy-related proteins, such as beclin-1 and SQSTM1/p62³⁹.

Kaempferol-immobilized titanium dioxide (TiO₂) increased osteogenic activity in rat bone marrow stromal cells (rBMSCs) isolated from femurs of 6-week-old female Sprague–Dawley rat femurs⁴⁰. TiO₂ is usually used for endosseous implant materials, and two samples of alkali-treated TiO₂ were evaluated in this study: the coprecipitation sample (Al-cK), immersed in DPBS containing 50 μ g kaempferol/100% ethanol, and the adsorption sample (Al-aK), in which 50 μ g kaempferol/100% ethanol was dropped onto control samples⁴⁰. The results showed that the calcium deposition of rBMSCs after 7 days on Al-aK was significantly higher than in the control, Al-Ti, and Al-cK samples⁴⁰. In addition, calcium deposition in both the Al-aK and Al-cK samples was significantly higher than in the control and Al-Ti sample after 14 days of treatment⁴⁰. Furthermore, the mRNA expression of OB-related proteins, such as osteocalcin (*Bglap*), osteonectin (*Sparc*), osteopontin (*Spp1*), and Alpl in rBMSCs grown on Al-aK and Al-cK was higher than in rBMSCs grown on the control and Al-Ti on day 3 and 7⁴⁰.

Another study found that kaempferol stimulated the osteogenic differentiation of cultured OBs by acting through estrogen receptor (ER) signaling evidenced by the induction effect on pERE-Luc-transfected cultured OBs⁴¹. Primary rat OBs were obtained from calvarial bones from 2-day-old neonatal Sprague–Dawley rats. OBs were cultured for 21 days and treated with kaempferol (10 μ M) or 17 β -estradiol (100 nM) in the presence of β -glycerophosphate (20 ng/mL) at 3-day intervals⁴¹. In OBs expressing pERE-Luc, 50 μ M kaempferol and 17 β -estradiol increased luciferase activity in a dose-dependent manner⁴¹. Furthermore, 30 μ M kaempferol and 17 β -estradiol increased Alpl activity and osteoblastic mineralization⁴¹. However, pre-treatment with ICI 182,780 (estrogen receptor inhibitor) fully blocked kaempferol-induced and 17 β -estradiol pERE-Luc activity and Alpl activity, indicating that kaempferol acts via ER activation⁴¹. In addition, kaempferol and 17 β -estradiol treatment of OBs significantly increased the transcription of numerous genes of bone differentiation markers, such as *Col1*, *Sparc*, *Bglap*, *Runx2*, and *Sp7*; this transcription was also blocked by pre-treatment of ICI 182,780⁴¹.

Another naturally occurring flavonoid is luteolin (3',4',5,7-tetrahydroxyflavone), which typically appears in glycosylated forms in celery, green pepper, perilla leaf, and chamomile tea and as an aglycone in perilla seeds⁴². A study on the MG63 OB cell line reported that 10^{-6} M luteolin treatment for 24 h enhanced OB-related gene expression, including expression of *Runx2*, *Alpl*, *Col1*, *Sp7*, and *Bglap*⁴³. Luteolin also has an anabolic effect on osteoblastic MC3T3-E1 cells through an estrogen-mediated mechanism²¹. For example, luteolin significantly enhanced collagen production in osteoblastic MC3T3-E1 cells (at 1 μ M), *Alpl* activity (at 0.1 and 1 μ M), and *Bglap* secretion (at 1 and 10 μ M) after 7 days of culture²¹. However, the effects of luteolin on increasing collagen synthesis and *Alpl* activity were inhibited by the anti-estrogen drug tamoxifen, indicating that luteolin is involved partly in the mechanism of estrogen action in osteoblastic cells²¹.

Crao *et al.* (2013) conducted a study on OCs differentiated from murine macrophage RAW 264.7 cells from ATCC and bone marrow mononuclear (BMM) cells isolated from tibias and femurs of 6-week-old CD-1 (5 days of RANKL and M-CSF stimulation with or without luteolin). The EC_{50} for both cells was 1.2 mM and 2.5 mM respectively. Luteolin treatment inhibited bone resorption via disruption of OC V-ATPase⁴⁴. V-ATPases are recruited to the plasma membranes of polarized, active OCs during bone resorption, where they regulate extracellular acidification⁴⁴. Furthermore, luteolin decreased the surface area of the resorption pit, which reduced the overall volume of the pit while inhibiting OC bone resorption without altering OC actin ring formation⁴⁴.

Stilbenes

Flavonoids are the most prevalent phenolic chemicals found in food, whereas stilbenes are rarely found in the human diet⁵⁴⁻⁵⁶. Flavonoids can be found in plants, such as grapevine, berries, and peanuts⁵⁷. Two benzene rings connected by an isopropylene moiety to form a compact ring structure and separated by a double bond define the structure of stilbenes⁵⁵. **Table 1** shows the effects of stilbenes on OBs and OCs. Piceatannol (3,3',4,5'-tetrahydroxy-trans-stilbene), or PIC, is found in grapes, passion fruit, white tea, Japanese knotweed, Asian legume, and Korean rhubarb. PIC exhibits antioxidant, antitumor, and anti-inflammatory activities, without toxicity in humans⁵⁸. Chang *et al.* (2006) reported that PIC stimulates MG-63 and hFOB (both are OB-like cell lines) maturation and differentiation. PIC treatment did

not improve cell proliferation but significantly increased *Alpl* (48 h treatment) and *Bglap* (72 h treatment) protein and gene expression at 0.1 – 20 μ M. PIC treatment also increased *Col1* synthesis (72 h treatment) and mineralization (96 h treatment)⁵⁹. In addition, PIC increased the expression of *Bmp2* at both the transcriptional and translational level in a time- (6 – 24 h) and dose-dependent manner (1 – 2 μ M). Therefore, PIC treatment can increase the differentiation of MG-63 and hFOB cells from the cell maturation stage of development to the matrix maturation stage⁵⁹.

PIC also significantly affects OC differentiation and bone resorption⁵¹. OCs were differentiated from RAW264.7 cells via RANKL and M-CSF stimulation. PIC significantly reduced TRAP-positive OCs and inhibited OC development in a dose-dependent manner (0, 2.5, 5, 10, 20, 40 mM) after 4 days of treatment⁵¹. The treatment also significantly reduced bone resorption pits, increased mature OC apoptosis, and decreased mature OC survival in a dose-dependent manner⁵¹. PIC treatment reduced the mRNA expression of NFATc1, dendritic cell-specific transmembrane protein (*Dcstamp*), *Ctsk*, matrix metalloproteinase-9 (*Mmp9*), and TRAP induced by RANKL. In addition, PIC treatment inhibited the phosphorylation of osteoclastic genes, including JNK, ERK1/2, nuclear factor kappa B (NF- κ B), p65, I κ B kinase alpha (I κ B α), and serine/threonine kinase (AKT)⁵¹.

Lignans

Lignans are a class of diphenolic compounds that are produced when two phenylpropanoid C6-C3 units are combined at the β and β' carbon and can be further linked by ether, lactone, or carbon bonds⁶⁰. However, when the molecular linkage of monomers occurs the other way around, the compound is classified as a "neolignane"⁶¹. Lignan is found in plants, such as flaxseed, sesame, and seeds of *Arctium lappa*⁶². **Table 1** shows the effects of lignan on OBs and OCs.

Gastrodin (GSTD), also known as gastrodia glycoside, is a phenolic compound that is found in *Gastrodia elata*, a well-known Chinese medicine⁶³. It has been used for many years as an anticonvulsant, analgesic, and sedative agent against vertigo, general paralysis, epilepsy, and tetanus⁶³. Liu *et al.* (2018) reported that this compound has potential in improving osteoporosis. Their study was conducted on dexamethasone (DEX)-induced cellular dysfunction of MC3T3-E1 OBs. GSTD ($\leq 100 \mu$ M) 2 h pretreatment was able to maintain the cell viability of




Figure 2: Schematic representation of the potential effects of polyphenols on osteoblast (OBs). Polyphenols upregulated bone morphogenetic protein-2 (*Bmp2*) and activate Smad proteins through a complex serine threonine receptor mechanism which subsequently induce the differentiation of bone marrow stem cells into OBs and modulate the expression of OBs related genes such as the runt related transcription factor 2 (*Runx2*) and alkaline phosphatase (*Alp*)^{45,46}. *Runx2* is an important transcription factor of osteogenesis, as it regulates the expression of OBs differentiation marker genes including osterix (*Sp7*), osteopontin (*Spp1*), osteocalcin (*Bglap*) as well as collagen type 1 (*Col1*)^{47,48}. Polyphenols also increased the production of calcium, phosphorus and *Col1* which indicates OBs mineralization and bone growth⁴⁹. Some polyphenols like (2*S*,3*S*)-Aromadendrin-6-*C*- β -*D*-glucopyranoside (AG) from the extract of *Ulmus wallichiana* are able to protect the differentiated OBs from serum deprivation-induced apoptosis³⁴. Kaempferol stimulates the osteogenic differentiation of cultured OBs by acting through the estrogen receptor (ER) signaling which subsequently increase the transcription of genes for several bone differentiation markers, (*Col1*, *Runx2*, *Bglap*, *Spp1* and *Sp7*)⁴¹.

MC3T3-E1 OBs at high concentrations of DEX ($\geq 50 \mu\text{M}$) following 24 h of exposure²². Furthermore, 7 days of 1–5 μM GSTD treatment significantly increased *Alpl* activity, which was reduced by DEX²². In addition, via the NRF2 signaling pathway, GSTD promoted osteogenesis and maintained the balance between adipogenesis²². Treatment enhanced the expression of bone osteogenic markers, such as *Bmp2*, *Runx2*, *Sp7*, and *Bglap*²². In addition, GSTD treatment enhanced the formation of calcium nodules, up-regulating OB osteogenic differentiation and enhancing the maturation process of MC3T3-E1 cells²². Pre-treatment with GSTD for 1 h also significantly re-

duced DEX-induced apoptosis of OBs²².

An *in vitro* study conducted by Zhou *et al.* (2017) reported that GSTD suppressed osteoclastogenesis by downregulating the nuclear factor-activated T cells c1 (NFATc1) signaling pathway while promoting osteointegration³³. OCs were derived from BMM cells via RANKL and M-CSF stimulation. GSTD (2 and 10 μM) suppressed RANKL-induced OC differentiation in the early stage of culture (day 0–2) in a dose-dependent manner and attenuated OC differentiation at the terminal stage of culture by inhibiting the migration of OCs to resorb into the bone slice²². Moreover, GSTD reduced the expression of NFATc1




Figure 3: Schematic representation of potential effects of polyphenols on osteoclasts (OCs). Receptor activator of nuclear factor- κ B ligand (RANKL) binds with RANK on preOCs, TNF receptor-associated factor (TRAF) 6 is recruited, which leads to activation of various transcription factors such as mitogen activated protein kinases (MAPK) including c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38, c-Fos, nuclear factor kappa B (NF- κ B), and nuclear factor of activated T-cell (NFATc1)^{39,50}. c-Fos activate activator protein-1 (AP-1) and interacts with NFATc1^{33,51}. This regulates the expression of tartrate-resistant acid phosphatase (TRAP), matrix metalloproteinase-9, 13 (Mmp9, Mmp13) and cathepsin K (Ctsk)³. Polyphenols has been found to be able to reduce the RANKL-induced differentiation of OCs by inhibiting the expression of mRNAs related to OC differentiation, including TRAP, Ctsk, Mmp9, Mmp13 and NFATc1 in primary osteoclastic cells^{33,51}. Osteoprotegerin (Tnfrsf11b) prevents OCs formation and osteoclastic bone resorption by inhibiting the RANKL–RANKL receptor interaction³⁵. Swarnkar *et al.*, (2011) has found that polyphenols increased the production Tnfrsf11b which subsequently inhibit OCs differentiation. The binding of macrophage colony-stimulating factor (M-CSF) to colony-stimulating factor 1 receptor (c-Fms receptor) will result in enhanced OCs precursor proliferation and survival through the ERK and serine/threonine kinase (AKT) pathways⁵². Polyphenols has been found to be able to inhibit OCs differentiation of bone marrow precursor cells to OCs in the presence of RANKL and M-CSF and suppressed the activation of AKT^{34,51}. Dendritic cell-specific transmembrane protein (Dcstamp) possibly interact with NFATc1 for successful OCs differentiation⁵³. Zhou *et al.*, (2017) have shown that polyphenols can inhibit gene expression of Dcstamp thus preventing OCs maturation and migration.

in BMM cells on days 1 – 3, which subsequently reduced the fusion and migration of pre-OCs by down-regulating OC-specific gene expression, including the expression of *TRAP*, *Ctsk*, and *Dcstamp*³³.

Phenolic acids

Phenolic acid is another bioactive compound that exists in many plants. In its structure, hydrogen atoms on benzene rings are replaced by a carboxylic acid group with at least one hydroxyl⁶⁴. Benzoic acids (gallic, p-hydroxybenzoic, vanillic, and syringic acid)

and cinnamic acid are the two major phenolic chemicals from which phenolic acid is generated (caffeic, ferulic, sinapic, and p-coumaric acids)⁶⁵.

Tannic acid (TA) is a naturally occurring polyphenol that is found in red wine, beer, coffee, black tea, green tea, grapes, pears, bananas, sorghum, black-eyed peas, lentils, and chocolate⁶⁶. TA has been used as a food additive, a medication to treat diarrhea, a local astringent, an antidote for poisoning, and a remedy for burns⁶⁷. It also possesses antioxidant, antimutagenic, and anticarcinogenic activities⁶⁷. TA

treatment is more effective in increasing hFOB 1.19 cell proliferation ($EC_{50} = 2.94$ M) than pamidronate (PAM) ($EC_{50} = 15.27$ M), a nitrogen-containing bisphosphonate that is used to inhibit bone resorption²⁰. TA treatment also increased the calcium phosphate (Ca/P) molar ratio in a time-dependent manner (day 3 and day 10), which is crucial for the mineralization of the extracellular matrix²⁰. Moreover, treatment of hFOB 1.19 cells with TA produced a confluent monolayer of cells, a significant number of bone nodules, and large globular accretions with flattened orientation²⁰. Compared with cells treated with PAM, TA produced better results in terms of proliferation, morphological alterations, and mineralization²⁰. In contrast, a study by Steffi *et al.* (2019) reported that TA treatment of RAW 264.7 cells reduced RANKL-stimulated TRAP activity on day 5 of culture. The treatment also reduced the OC number measured by total DNA on day 5 of culture⁶⁸. Furthermore, the treatment reduced the actin ring formation of OCs⁶⁸. The effects of phenolic acid on OBs and OCs are presented in **Table 1**.

Following consumption of coffee, vegetables, blueberries, and other fruits, a polyphenol molecule called 3(3-hydroxyphenyl) propionic acid (PPA), a phenolic acid that is generated by the gut microbiota, is released into the bloodstream^{69,70}. The breakdown of chlorogenic acid by the gut microbiota results in the production of PPA, which is absorbed and oxidized in the liver before entering the circulation⁶⁹. PPA treatment (1–100 $\mu\text{g}/\text{dL}$) increased Alpl production in bone marrow-derived mouse stromal cell line ST2 cells after 10 days of culture⁷⁰. In addition, 24 h of treatment increased the mRNA expression of various OB differentiation markers, including Col1 and Spp1⁷⁰. Moreover, Zhao *et al.* (2020) reported that PPA can suppress osteoclastogenesis through the RANKL-RANK independent pathway in RAW 264.7 cells and non-adherent bone marrow cells isolated from 4-week-old female C57BL/J mice. PPA treatment (1 – 100 $\mu\text{g}/\text{dL}$) with RANKL and M-CSF has been shown to decrease the number of OCs and bone resorption pits per well⁶⁹. In addition, PPA treatment for 3 days inhibited RANKL-induced NFATc1, cFos, Mmp9, and Ctsk protein expression. PPA reduced the expression of the second messenger GPR109A on the surface of pre-OCs, which increased the level of cAMP inside cells and inhibited the expression of OC-specific genes and OC development⁶⁹.

POSSIBLE MOLECULAR MECHANISMS INVOLVED ON THE EFFECTS OF POLYPHENOLS ON OBS AND OCS

The BMP signal transduction pathway regulates OB formation and activation via both conventional Smad-dependent (Bmp ligands, receptors, and Smads) and non-canonical Smad-independent signaling pathways (p38 MAPK pathway)⁴⁵. A previous study demonstrated that polyphenols promoted OB activation and development via the Smad-dependent signaling pathway^{45,46}. Polyphenols up-regulate *Bmp2* and activate Smad proteins through a complex serine threonine receptor mechanism that subsequently induces the differentiation of bone marrow stem cells into OBs and modulates the expression of OB-related genes (*Runx2*, *Alpl*)^{45,46}.

Runx2/Cbfa is a member of the runt family of transcription factors 1 and is crucial to several stages of bone development⁷¹. The roles of *Runx2* include the establishment of the lineage of OBs from multipotent mesenchymal cells, promotion of early OB differentiation, and inhibition of late OB differentiation⁷². *Runx2* regulates the expression of *Sp7*, which is required for OB differentiation and bone formation, by directly binding to the *Sp7* promoter^{47,48}. *Runx2* is also involved in the OB-selective expression of BSP when interaction occurs between two types of enhancers: a homeodomain protein-binding site (the C site) and two *Runx2*-binding sites, R1 and R2⁷³. BSP belong to the “small integrin-binding ligand and N-linked glycoproteins” (SIBLING), an extracellular matrix protein family of mineralized tissues that is involved in the initial steps of bone mineralization⁷⁴. *Mmp13* is another example of an OB-specific gene that is influenced by *Runx2*^{75,76}. *Mmp13* is crucial in the bone remodeling process, and a study found that due to the manipulation of the OC lacunar-canalicular network remodeling in the cortical bone, *Mmp13*-knockout mice had decreased resistance to fractures in their long bones, indicating that *Mmp13* is required for the proper distribution of mineral density in cortical bone⁷⁷. Furthermore, *Runx2* down-regulates the expression of *Htra1* by binding to the *Htra1* promoter at -252 bp and -84 bp, which subsequently promotes the osteoblastic differentiation of primary mesenchymal progenitor cells¹⁷. *Runx2* determines the OB lineage from pluripotent mesenchymal cells, enhances OB differentiation at an early stage, and inhibits OB differentiation at a late stage. Polyphenols increase the production of calcium, phosphorus, and Col1, which indicates OB mineralization and bone growth⁴⁹. Some polyphenols, like

(2S,3S)-aromadendrin-6-C- β -D-glucopyranoside (AG) from the extract of *U. wallichiana*, can protect the differentiated OBs from serum deprivation-induced apoptosis³⁴. In addition, polyphenols stimulate OB formation and mineralization through the ER. Estrogen-induced messengers are effectively transmitted in OBs by estrogen receptor alpha (ER α)⁷⁸. Through ER signaling, polyphenols, like kaempferol, induce osteogenic differentiation of cultured OBs, which subsequently increases the transcription of numerous genes of bone differentiation markers (*Col1*, *Runx2*, *Bglap*, *Spp1*, and *Sp7*)⁴¹.

OC precursors differentiate into mature OCs primarily through interactions with two cytokines: M-CSF and RANKL⁷⁹. OC precursor cells require signals for proliferation and survival from M-CSF, which binds to colony-stimulating factor 1 receptor (c-Fms), while RANKL-to-RANK interactions are important for differentiation, resorptive activity, and the survival of mature OCs⁵². When RANKL binds to RANK on pre-OCs, TRAF6 is recruited, which activates various transcription factors, such as MAPKs (JNK, ERK, p38), c-Fos, NF- κ B, and NFATc1^{39,50,80}. c-Fos is essential for the activation of activator protein-1 (AP-1), which interacts with NFATc1⁸¹. This interaction regulates the expression of genes necessary for OC differentiation and subsequently regulates several OC-related genes, including *TRAP*, *Mmp9*, *Mmp13*, and *Ctsk*⁵⁰. Polyphenols can reduce the RANKL-induced differentiation of OCs by inhibiting the expression of mRNAs related to OC differentiation, including *TRAP*, *Ctsk*, *Mmp9*, *Mmp13*, and *NFATc1* in primary osteoclastic cells^{33,51,82}. Tnfrsf11b, a soluble RANKL decoy receptor that is primarily generated by OBs, inhibits the interaction between RANKL and RANKL receptors, thereby hindering the development of OCs and inhibiting osteoclastic bone resorption³⁵. Swarnkar *et al.* (2011) found that polyphenols increased the production Tnfrsf11b, which subsequently inhibited OC differentiation.

On the other hand, the binding of M-CSF to c-Fms receptor results in increased OC precursor proliferation and survival through the ERK and PI3K/AKT pathways⁵². Polyphenols inhibit the differentiation of bone marrow precursor cells to OCs in the presence of RANKL and M-CSF and suppress the activation of AKT^{34,51}. Dcstamp is a multi-pass transmembrane protein, another master regulator of osteoclastogenesis that is essential for the cell-cell fusion of OC precursors during OC development^{53,83}. Dcstamp possibly interacts with NFATc1 to ensure successful OC differentiation⁵³. Zhou *et al.* (2017) reported that polyphenols can inhibit the gene expression of Dcstamp, thereby preventing OC maturation


and migration³³. **Figure 2** and **Figure 3** summarize the targeted pathways involved in bone formation and the suppression of OC function and survival.

CO-CULTURE

According to Sieberath *et al.* (2020), researchers have focused on the development of *in vitro* models using cell lines or primary cells to obtain more relevant pre-clinical results related to bone cell studies. This is due to the limitations and ethical issues faced when using animal models; therefore, if possible, they should be replaced with *in vitro* studies¹⁶. Co-culture provides a novel approach for the biological study of biomaterials, as the cellular environment in co-culture is closer to the *in vivo* environment than monoculture, with appropriate cell-cell interactions²⁶. The co-culture model can be established both in 2D and 3D arrangement, with or without a direct physical contact among different cell types, and static or dynamic systems (**Figure 4**)⁸⁴.

DIRECT OR INDIRECT CO-CULTURE: ADVANTAGES AND LIMITATIONS

Co-culture methods involve the cultivation of two or more different cell types and can be performed in one culture dish or well either directly or indirectly⁸⁵. In direct co-culture systems, cells are mixed in the culture environment and can make direct contact with each other⁸⁶. Direct co-culture can be performed in almost any cell culture dish, for example, by layering two cell types on top of each other. In contrast, indirect co-culture is performed by separating different cell types using inserted porous membranes⁸⁵. Cells in direct co-culture can connect with each other in various ways, such as through gap junctions, tight junctions, and desmosomes⁸⁶. Direct cell-cell contact is reported to play an important role in various mechanisms, and direct co-culture methods allow physical interactions and the analysis of autocrine/paracrine signals^{84,85}. Therefore, the direct co-culture system mimics *in vivo* conditions²⁴. However, the inability to distinguish the different contributions of the diverse cell types, as the cells are mixed together in the same environment, is a clear disadvantage of direct co-culture⁸⁴. Despite its simple set-ups, this methodology is associated with numerous technical difficulties, whereas indirect co-culture takes advantage of cell cultures inserted with porous membranes to keep the co-cultivated cell populations separate^{24,26}. For example, in direct co-culture, the growth dominance of OBs causes the massive death of OCs, which is unfavorable for long-term culture⁸⁷.



Therefore, cell ratios must be optimized²⁴. In addition, it is difficult to isolate a single type of cell from the co-culture system, which limits the methods available to analyze cells separately^{24,87}.

In indirect co-cultures, cells are physically separated; however, culture medium and other molecules, such as proteins, extracellular vesicles, and soluble factors, released by one cell type can still cross the pores and influence the behavior, proliferation, maturation, and differentiation of the other cell type(s) through paracrine signaling⁸⁴. Moreover, cells can be evaluated separately, and cell migration can also be analyzed²⁴. The limitation is that the physical receptor-mediated cell-cell interactions are hindered, and the large volumes of cells needed might limit the oxygen supply in the bottom wells^{24,84}. In contrast, direct co-culture allows for a uniform medium height and oxygen supply for both cell types, and smaller volumes of cells are needed in direct co-culture than in transwell co-culture²⁴.

CONCLUSION

Osteoporosis is becoming a major public health problem, and its incidence is increasing. Consequently, antiresorptive and anabolic therapies have been developed for the treatment of osteoporosis using various drugs and biomaterials with the purpose of stimulating bone formation or suppressing OC function

and survival. According to previous studies, polyphenols, especially bioactive phenolics, have positive effects on bone metabolism in osteoporosis. OBs and OCs are the most conventional cell types for studying bone diseases *in vitro* as these cells are the crucial components of osteogenesis and remodeling. These cells do not behave independently of one another, and various communication pathways between them have been discovered. Therefore, it is imperative to further investigate the effects of polyphenols in co-culture models, as these models allow for optimal cell-cell interactions and mimic the *in vivo* environment more accurately than monoculture.

ABBREVIATIONS

Alpl: alkaline phosphatase, **AKT:** serine/threonine kinase, **AP-1:** activator protein-1, **Bglap:** osteocalcin, **BMP:** bone morphogenetic protein, **c-Fms:** colony-stimulating factor 1 receptor, **Coll1:** collagen type 1, **Ctsk:** Cathepsin K, **Dcstamp:** dendritic cell-specific transmembrane protein, **ERK:** extracellular signal-regulated kinase, **JNK:** c-Jun N-terminal kinase, **M-CSF:** macrophage colony stimulating factor 1, **NFATc1:** nuclear factor-activated T cells c1, **NF-κB:** nuclear factor kappa B, **Sp7:** osterix, **Sparc:** osteonectin, **Spp1:** osteopontin, **RANKL:** receptor activator of nuclear factor-κB ligand, **RUNX2:** runt related transcription factor 2, **Tnfrsf11b:** osteoprotegerin, **TRAP:** tartrate-resistant acid phosphatase

ACKNOWLEDGMENTS

The authors were grateful to the Ministry of Education, Malaysia for funding the publication cost of this work under the Fundamental Research Grant Scheme (FRGS) grant number FRGS/1/2020/STG01/USM/02/16.

AUTHOR'S CONTRIBUTIONS

Hermizi Hapidin developed the idea for the study and coordinated the article; Nurul Husna Azizul collected most of the provided data and drafted the article; Hasmah Abdullah, Maryam Azlan, Azlina Ahmad, and Ima Nirwana Soleiman participated in the critical revision of the article; and all authors read and approved the final version of the article.

FUNDING

Ministry of Education, Malaysia has funded the publication cost of this work under the Fundamental Research Grant Scheme (FRGS) grant number FRGS/1/2020/STG01/USM/02/16.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

- Kim JM, Lin C, Stavre Z, Greenblatt MB, Shim JH. Osteoblast-Osteoclast Communication and Bone Homeostasis. *Cells*. 2020;9(9):2073. PMID: 32927921. Available from: [10.3390/cells9092073](https://doi.org/10.3390/cells9092073).
- Jolly JJ, Chin KY, Farhana MF, Alias E, Chua KH, Hasan WN, et al. Optimization of the Static Human Osteoblast/Osteoclast Co-culture System. *Iran J Med Sci*. 2018;43(2):208.
- Chen X, Wang Z, Duan N, Zhu G, Schwarz EM, Xie C. Osteoblast-osteoclast interactions. *Connective Tissue Research*. 2018;59(2):99–107. PMID: 28324674. Available from: [10.1080/03008207.2017.1290085](https://doi.org/10.1080/03008207.2017.1290085).
- Yamashita T, Takahashi N, Udagawa N. New roles of osteoblasts involved in osteoclast differentiation. *World J Orthop*. 2012;3(11):175. Available from: [10.5312/wjo.v3.i11.175](https://doi.org/10.5312/wjo.v3.i11.175).
- Zhang S, Wang X, Li G, Chong Y, Zhang J, Guo X, et al. Osteoclast regulation of osteoblasts via RANK-RANKL reverse signal transduction in vitro. *Mol Med Rep*. 2017;16(4):3994. Available from: [10.3892/mmr.2017.7039](https://doi.org/10.3892/mmr.2017.7039).
- Simon D, Derer A, Andes FT, Lezuo P, Bozec A, Schett G. Galectin-3 as a novel regulator of osteoblast-osteoclast interaction and bone homeostasis. *Bone*. 2017;105:35–41. PMID: 28822790. Available from: [10.1016/j.bone.2017.08.013](https://doi.org/10.1016/j.bone.2017.08.013).

- Sims NA, Ng KW. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. *Current Osteoporosis Reports*. 2014;12(1):98–106. PMID: 24477416. Available from: [10.1007/s11914-014-0196-1](https://doi.org/10.1007/s11914-014-0196-1).
- Jones GL, Motta A, Marshall MJ, Haj AJE, Cartmell SH. Osteoblast: osteoclast co-cultures on silk fibroin, chitosan and PLLA films. *Biomaterials*. 2009;30(29):5376–84. PMID: 19647869. Available from: [10.1016/j.biomaterials.2009.07.028](https://doi.org/10.1016/j.biomaterials.2009.07.028).
- Drake MT, Clarke BL, Lewiecki EM. The Pathophysiology and Treatment of Osteoporosis. *Clinical Therapeutics*. 2015;37(8):1837–50. PMID: 26163201. Available from: [10.1016/j.clinthera.2015.06.006](https://doi.org/10.1016/j.clinthera.2015.06.006).
- Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. *Journal of Internal Medicine*. 2015;277(6):650–61. PMID: 25832448. Available from: [10.1111/joim.12369](https://doi.org/10.1111/joim.12369).
- Sözen T, Özişl, Başaran NÇ. An overview and management of osteoporosis. *Eur J Rheumatol*. 2017;4(1):46. Available from: [10.5152/eurjrheum.2016.048](https://doi.org/10.5152/eurjrheum.2016.048).
- Tu KN, Lie JD, Wan KKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A Review of Treatment Options. *Pharmacy and Therapeutics*. 2018;43(2):92.
- Chan CY, Subramaniam S, Chin KY, Ima-Nirwana S, Muhammad N, Fairus A. Levels of knowledge, beliefs, and practices regarding osteoporosis and the associations with bone mineral density among populations more than 40 years old in Malaysia. *International Journal of Environmental Research and Public Health*. 2019;16(21):4115. PMID: 31731507. Available from: [10.3390/ijerph16214115](https://doi.org/10.3390/ijerph16214115).
- Akkawi I, Zmerly H. Osteoporosis: current Concepts. *Joints*. 2018;6(2):122–7. PMID: 30051110. Available from: [10.1055/s-0038-1660790](https://doi.org/10.1055/s-0038-1660790).
- Casarrubios L, Gómez-Cerezo N, Feito MJ, Vallet-Regí M, Arcos D, Portolés MT. Incorporation and effects of mesoporous SiO₂-CaO nanospheres loaded with ipriflavone on osteoblast/osteoclast cocultures. *European Journal of Pharmaceutics and Biopharmaceutics*. 2018;133:258–68. PMID: 30385420. Available from: [10.1016/j.ejpb.2018.10.019](https://doi.org/10.1016/j.ejpb.2018.10.019).
- Sieberath A, Bella ED, Ferreira AM, Gentile P, Eglin D, Dalgarno K. A Comparison of Osteoblast and Osteoclast In Vitro Co-Culture Models and Their Translation for Preclinical Drug Testing Applications. *International Journal of Molecular Sciences*. 2020;21(3):912. PMID: 32019244. Available from: [10.3390/ijms21030912](https://doi.org/10.3390/ijms21030912).
- Iyyanar PP, Thangaraj MP, Eames BF, Nazarali AJ. HtrA1 is a novel transcriptional target of Runx2 that promotes osteogenic differentiation. *Cell Physiol Biochem*. 2019;53(5):832–850. Available from: [10.33594/000000176](https://doi.org/10.33594/000000176).
- Iwata JI, Hosokawa R, Sanchez-Lara PA, Urata M, Slavkin H, Chai Y. Transforming Growth Factor- β Regulates Basal Transcriptional Regulatory Machinery to Control Cell Proliferation and Differentiation in Cranial Neural Crest. *Journal of Biological Chemistry*. 2010;285(7):4975–4982. Available from: [10.1074/jbc.M109.035105](https://doi.org/10.1074/jbc.M109.035105).
- Lee B, Jo S, Kim SM, Cho ML, Park SH, Youn J, et al. Poly- γ -glutamic acid suppresses osteoclastogenesis in human osteoclast precursors and prevents joint damage in a collagen-induced murine arthritis model. *Immunology Letters*. 2018;203:80–86. Available from: [10.1016/j.imlet.2018.09.004](https://doi.org/10.1016/j.imlet.2018.09.004).
- Hapidin H, Romli NA, Abdullah H. Proliferation study and microscopy evaluation on the effects of tannic acid in human fetal osteoblast cell line (hFOB 1.19). *Microscopy Research and Technique*. 2019;82(11):1928–40. PMID: 31423711. Available from: [10.1002/jemt.23361](https://doi.org/10.1002/jemt.23361).
- Choi EM. Modulatory effects of luteolin on osteoblastic function and inflammatory mediators in osteoblastic MC3T3-E1 cells. *Cell Biology International*. 2007;31(9):870–7. PMID: 17368935. Available from: [10.1016/j.cellbi.2007.01.038](https://doi.org/10.1016/j.cellbi.2007.01.038).

22. Liu S, Fang T, Yang L, Chen Z, Mu S, Fu Q. Gastrodin protects MC3T3-E1 osteoblasts from dexamethasone-induced cellular dysfunction and promotes bone formation via induction of the NRF2 signaling pathway. *International Journal of Molecular Medicine*. 2018;41(4):2059–69. PMID: 29393365. Available from: [10.3892/ijmm.2018.3414](https://doi.org/10.3892/ijmm.2018.3414).
23. Kang YK, Zhang MC. IL-23 promotes osteoclastogenesis in osteoblast-osteoclast co-culture system. *Genetics and Molecular Research*. 2014;13(2):4673–9. PMID: 25036517. Available from: [10.4238/2014.June.18.10](https://doi.org/10.4238/2014.June.18.10).
24. Zhu S, Ehnert S, RoußM, Häussling V, Aspera-Werz RH, Chen T. From the Clinical Problem to the Basic Research-Co-Culture Models of Osteoblasts and Osteoclasts. *International Journal of Molecular Sciences*. 2018;19(8):2284. PMID: 30081523. Available from: [10.3390/ijms19082284](https://doi.org/10.3390/ijms19082284).
25. Bernhardt A, Thieme S, Domaschke H, Springer A, Rösen-Wolff A, Gelinsky M. Crosstalk of osteoblast and osteoclast precursors on mineralized collagen-towards an in vitro model for bone remodeling. *J Biomed Mater Res A*. 2010;95(3A):848–56.
26. Meng G, Wu X, Yao R, He J, Yao W, Wu F. Effect of zinc substitution in hydroxyapatite coating on osteoblast and osteoclast differentiation under osteoblast/osteoclast co-culture. *Regenerative Biomaterials*. 2019;6(6):349–59. PMID: 32440356. Available from: [10.1093/rb/rbz001](https://doi.org/10.1093/rb/rbz001).
27. Williamson G. The role of polyphenols in modern nutrition. *Nutrition Bulletin*. 2017;42(3):226–35. PMID: 28983192. Available from: [10.1111/nbu.12278](https://doi.org/10.1111/nbu.12278).
28. Lorenzo CD, Colombo F, Biella S, Stockley C, Restani P. Polyphenols and Human Health: The Role of Bioavailability. *Nutrients*. 2021;13(1):273. PMID: 33477894. Available from: [10.3390/nu13010273](https://doi.org/10.3390/nu13010273).
29. Rasouli H, Farzaei MH, Khodarahmi R. Polyphenols and their benefits: A review. *International Journal of Food Properties*. 2017;20:1700–41.
30. Shavandi A, Bekhit AE, Saeedi P, Izadifar Z, Bekhit AA, Khademhosseini A. Polyphenol uses in biomaterials engineering. *Biomaterials*. 2018;167:91–106. PMID: 29567389. Available from: [10.1016/j.biomaterials.2018.03.018](https://doi.org/10.1016/j.biomaterials.2018.03.018).
31. Ding S, Jiang H, Fang J. Regulation of Immune Function by Polyphenols. *J Immunol Res*. 2018;2018:1264074. Available from: [10.1155/2018/1264074](https://doi.org/10.1155/2018/1264074).
32. Terahara N. Flavonoids in foods: a review. *Natural Product Communications*. 2015;10(3):521–8. PMID: 25924542. Available from: [10.1177/1934578X1501000334](https://doi.org/10.1177/1934578X1501000334).
33. Zhou F, Shen Y, Liu B, Chen X, Wan L, Peng D. Gastrodin inhibits osteoclastogenesis via down-regulating the NFATc1 signaling pathway and stimulates osseointegration in vitro. *Biochemical and Biophysical Research Communications*. 2017;484(4):820–6. PMID: 28161640. Available from: [10.1016/j.bbrc.2017.01.179](https://doi.org/10.1016/j.bbrc.2017.01.179).
34. Swarnkar G, Sharan K, Siddiqui JA, Chakravarti B, Rawat P, Kumar M. A novel flavonoid isolated from the steam-bark of *Ulmus wallichiana* planchon stimulates osteoblast function and inhibits osteoclast and adipocyte differentiation. *European Journal of Pharmacology*. 2011;658(2-3):65–73. PMID: 21376034. Available from: [10.1016/j.ejphar.2011.02.032](https://doi.org/10.1016/j.ejphar.2011.02.032).
35. Udagawa N, Koide M, Nakamura M, Nakamichi Y, Yamashita T, Uehara S. Osteoclast differentiation by RANKL and OPG signaling pathways. *Journal of Bone and Mineral Metabolism*. 2021;39(1):19–26. PMID: 33079279. Available from: [10.1007/s00774-020-01162-6](https://doi.org/10.1007/s00774-020-01162-6).
36. Santos JM, Lins TL, Barberino RS, Menezes VG, Gouveia BB, Matos MH. Kaempferol promotes primordial follicle activation through the phosphatidylinositol 3-kinase/protein kinase B signaling pathway and reduces DNA fragmentation of sheep preantral follicles cultured in vitro. *Molecular Reproduction and Development*. 2019;86(3):319–29. PMID: 30624818. Available from: [10.1002/mrd.23107](https://doi.org/10.1002/mrd.23107).
37. Wattel A, Kamel S, Mentaverri R, Lorget F, Prouillet C, Petit JP. Potent inhibitory effect of naturally occurring flavonoids quercetin and kaempferol on in vitro osteoclastic bone resorption. *Biochemical Pharmacology*. 2003;65(1):35–42. PMID: 12473376. Available from: [10.1016/S0006-2952\(02\)01445-4](https://doi.org/10.1016/S0006-2952(02)01445-4).
38. Wattel A, Kamel S, Prouillet C, Petit JP, Lorget F, Offord E. Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF- κ B and AP-1. *Journal of Cellular Biochemistry*. 2004;92(2):285–95. PMID: 15108355. Available from: [10.1002/jcb.20071](https://doi.org/10.1002/jcb.20071).
39. Kim K, Kim TH, Ihn HJ, Kim JE, Choi JY, Shin HI. Inhibitory Effect of Purpurogallin on Osteoclast Differentiation in Vitro through the Downregulation of c-Fos and NFATc1. *International Journal of Molecular Sciences*. 2018;19(2):601. PMID: 29463002. Available from: [10.3390/ijms19020601](https://doi.org/10.3390/ijms19020601).
40. Tsuchiya S, Sugimoto K, Kamio H, Okabe K, Kuroda K, Okido M, et al. Kaempferol-immobilized titanium dioxide promotes formation of new bone: effects of loading methods on bone marrow stromal cell differentiation in vivo and in vitro. *Int J Nanomedicine*. 2018;13:1665. Available from: [10.2147/IJN.S150786](https://doi.org/10.2147/IJN.S150786).
41. Guo AJ, Choi RC, Zheng KY, Chen VP, Dong TT, Wang ZT. Kaempferol as a flavonoid induces osteoblastic differentiation via estrogen receptor signaling. *Chinese Medicine*. 2012;7(1):10. PMID: 22546174. Available from: [10.1186/1749-8546-7-10](https://doi.org/10.1186/1749-8546-7-10).
42. Jain R, Tiwari A. Monograph: Luteolin. *Matrix Science Medica*. 2020;4(3):88. Available from: <https://go.gale.com/ps/i.do?p=HRC&sw=w&issn=25210807&v=2.1&it=r&id=GALE%7CA629936833&sid=googleScholar&linkaccess=fulltext>.
43. Melguizo-Rodríguez L, Manzano-Moreno FJ, Illescas-Montes R, Ramos-Torrecillas J, Luna-Bertos E, Ruiz C. Bone Protective Effect of Extra-Virgin Olive Oil Phenolic Compounds by Modulating Osteoblast Gene Expression. *Nutrients*. 2019;11(8):1722. PMID: 31349732. Available from: [10.3390/nu11081722](https://doi.org/10.3390/nu11081722).
44. Crasto GJ, Kartner N, Yao Y, Li K, Bullock L, Datti A. Luteolin inhibition of V-ATPase α 3-d2 interaction decreases osteoclast resorptive activity. *Journal of Cellular Biochemistry*. 2013;114(4):929–41. PMID: 23129004. Available from: [10.1002/jcb.24434](https://doi.org/10.1002/jcb.24434).
45. Chen G, Deng C, Li YP. TGF- β and BMP signaling in osteoblast differentiation and bone formation. *International Journal of Biological Sciences*. 2012;8(2):272–88. PMID: 22298955. Available from: [10.7150/ijbs.2929](https://doi.org/10.7150/ijbs.2929).
46. Zou ML, Chen ZH, Teng YY, Liu SY, Jia Y, Zhang KW. The Smad Dependent TGF- β and BMP Signaling Pathway in Bone Remodeling and Therapies. *Frontiers in Molecular Biosciences*. 2021;8:593310. PMID: 34026818. Available from: [10.3389/fmolb.2021.593310](https://doi.org/10.3389/fmolb.2021.593310).
47. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. *Cell*. 2002;108(1):17–29. PMID: 11792318. Available from: [10.1016/S0092-8674\(01\)00622-5](https://doi.org/10.1016/S0092-8674(01)00622-5).
48. Nishio Y, Dong Y, Paris M, O'Keefe RJ, Schwarz EM, Drissi H. Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene. *Gene*. 2006;372(1-2):62–70. PMID: 16574347. Available from: [10.1016/j.gene.2005.12.022](https://doi.org/10.1016/j.gene.2005.12.022).
49. Ciosek Z, Kot K, Kosik-Bogacka D, -Arendarczyk N, Rotter I. The Effects of Calcium, Magnesium, Phosphorus, Fluoride, and Lead on Bone Tissue. *Biomolecules*. 2021;11(4):506. PMID: 33800689. Available from: [10.3390/biom11040506](https://doi.org/10.3390/biom11040506).
50. Chen X, Wang Z, Duan N, Zhu G, Schwarz EM, Xie C. Osteoblast-osteoclast interactions. *Connective Tissue Research*. 2018;59(2):99–107. PMID: 28324674. Available from: [10.1080/03080207.2017.1290085](https://doi.org/10.1080/03080207.2017.1290085).
51. Yan L, Lu L, Hu F, Shetti D, Wei K. Piceatannol attenuates RANKL-induced osteoclast differentiation and bone resorption by suppressing MAPK, NF- κ B and AKT signalling pathways and promotes Caspase3-mediated apoptosis of mature osteoclasts. *Royal Society Open Science*. 2019;6(6):190360. PMID: 31312498. Available from: [10.1098/rsos.190360](https://doi.org/10.1098/rsos.190360).

52. Kim JH, Kim N. Signaling Pathways in Osteoclast Differentiation. *Chonnam Med J.* 2016;52:12–7. Available from: [10.4068/cmj](https://doi.org/10.4068/cmj).
53. Chiu YH, Schwarz E, Li D, Xu Y, Sheu TR, Li J, et al. Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Osteoclast Differentiation via the Ca²⁺/NFATc1 axis. *J Cell Physiol.* 2017;232(9):2538. Available from: [10.1002/jcp.25638](https://doi.org/10.1002/jcp.25638).
54. Dzah CS, Duan Y, Zhang H, Boateng NAS, Ma H. Latest developments in polyphenol recovery and purification from plant by-products: A review. *Trends in Food Science & Technology.* 2020;99:375–88. Available from: [10.1016/j.tifs.2020.03.003](https://doi.org/10.1016/j.tifs.2020.03.003).
55. Kasiotis KM, Pratsinis H, Kletsas D, Haroutounian SA. Resveratrol and related stilbenes: their anti-aging and anti-angiogenic properties. *Food and Chemical Toxicology.* 2013;61:112–20. PMID: 23567244. Available from: [10.1016/j.fct.2013.03.038](https://doi.org/10.1016/j.fct.2013.03.038).
56. Flamini R, Mattivi F, Rosso MD, Arapitsas P, Bavaresco L. Advanced knowledge of three important classes of grape phenolics: anthocyanins, stilbenes and flavonols. *International Journal of Molecular Sciences.* 2013;14(10):19651–69. PMID: 24084717. Available from: [10.3390/ijms141019651](https://doi.org/10.3390/ijms141019651).
57. el Khawand T, Courtois A, Valls J, Richard T, Krisa S. A review of dietary stilbenes: sources and bioavailability. *Phytochemistry Reviews.* 2018;17(5):1007–29. Available from: [10.1007/s11101-018-9578-9](https://doi.org/10.1007/s11101-018-9578-9).
58. Banik K, Ranaware AM, Harsha C, Nitesh T, Girisa S, Deshpande V. Piceatannol: A natural stilbene for the prevention and treatment of cancer. *Pharmacological Research.* 2020;153:104635. PMID: 31926274. Available from: [10.1016/j.phrs.2020.104635](https://doi.org/10.1016/j.phrs.2020.104635).
59. Chang JK, Hsu YL, Teng IC, Kuo PL. Piceatannol stimulates osteoblast differentiation that may be mediated by increased bone morphogenetic protein-2 production. *European Journal of Pharmacology.* 2006;551(1-3):1–9. PMID: 17026990. Available from: [10.1016/j.ejphar.2006.08.073](https://doi.org/10.1016/j.ejphar.2006.08.073).
60. Durazzo A, Lucarini M, Camilli E, Marconi S, Gabrielli P, Lisciani S. Dietary Lignans: Definition, Description and Research Trends in Databases Development. *Molecules (Basel, Switzerland).* 2018;23(12):3251. PMID: 30544820. Available from: [10.3390/molecules23123251](https://doi.org/10.3390/molecules23123251).
61. Cui Q, Du R, Liu M, Rong L. Lignans and Their Derivatives from Plants as Antivirals. *Molecules.* 2020;25(1):183. PMID: 6982783. Available from: [10.3390/molecules25010183](https://doi.org/10.3390/molecules25010183).
62. Zhou Y, Zheng J, Li Y, Xu DP, Li S, Chen YM. Natural polyphenols for prevention and treatment of cancer. *Nutrients.* 2016;8(8):515. PMID: 27556486. Available from: [10.3390/nu8080515](https://doi.org/10.3390/nu8080515).
63. Wang L. Two new phenolic glycosides from the rhizome of *Gastrodia elata*. *Asian natural products research.* 2012;14(5):457–62. Available from: [10.1080/10286020.2012.669755](https://doi.org/10.1080/10286020.2012.669755).
64. Chen J, Yang J, Ma L, Li J, Shahzad N, Kim CK. Structure-antioxidant activity relationship of methoxy, phenolic hydroxyl, and carboxylic acid groups of phenolic acids. *Scientific Reports.* 2020;10(1):2611. PMID: 32054964. Available from: [10.1038/s41598-020-59451-z](https://doi.org/10.1038/s41598-020-59451-z).
65. Durazzo A, Lucarini M, Souto EB, Cicala C, Caiazza E, Izzo AA. Polyphenols: A concise overview on the chemistry, occurrence, and human health. *Phytotherapy Research.* 2019;33(9):2221–43. PMID: 31359516. Available from: [10.1002/ptr.6419](https://doi.org/10.1002/ptr.6419).
66. Gülçin I, Huyut Z, Elmastaş M, Aboul-Enein HY. Radical scavenging and antioxidant activity of tannic acid. *Arabian Journal of Chemistry.* 2010;3(1):43–53. Available from: [10.1016/j.arabjc.2009.12.008](https://doi.org/10.1016/j.arabjc.2009.12.008).
67. Khan NS, Ahmad A, Hadi SM. Anti-oxidant, pro-oxidant properties of tannic acid and its binding to DNA. *Chemo-Biological Interactions.* 2000;125(3):177–89. PMID: 10731518. Available from: [10.1016/S0009-2797\(00\)00143-5](https://doi.org/10.1016/S0009-2797(00)00143-5).
68. Steffi C, Shi Z, Kong CH, Wang W. Bioinspired polydopamine and polyphenol tannic acid functionalized titanium suppress osteoclast differentiation: a facile and efficient strategy to regulate osteoclast activity at bone-implant interface. *Journal of the Royal Society, Interface.* 2019;16(152):20180799. PMID: 30836894. Available from: [10.1098/rsif.2018.0799](https://doi.org/10.1098/rsif.2018.0799).
69. Zhao H, Lazarenko OP, Chen JR. Hippuric acid and 3-(3-hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL-RANK independent pathway. *Journal of Cellular Physiology.* 2020;235(1):599–610. PMID: 31271661. Available from: [10.1002/jcp.28998](https://doi.org/10.1002/jcp.28998).
70. Chen JR, Wankhade UD, Alund AW, Blackburn ML, Shankar K, Lazarenko OP. 3-(3-Hydroxyphenyl)-Propionic Acid (PPA) Suppresses Osteoblastic Cell Senescence to Promote Bone Accretion in Mice. *JBMR Plus.* 2019;3(9):e10201. Available from: [10.1002/jbm4.10201](https://doi.org/10.1002/jbm4.10201).
71. Otto F, Kanegane H, Mundlos S. Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. *Human Mutation.* 2002;19(3):209–16. PMID: 11857736. Available from: [10.1002/humu.10043](https://doi.org/10.1002/humu.10043).
72. Komori T. Runx2, a multifunctional transcription factor in skeletal development. *Journal of Cellular Biochemistry.* 2002;87(1):1–8. PMID: 12210716. Available from: [10.1002/jcb.10276](https://doi.org/10.1002/jcb.10276).
73. Roca H, Phimpilai M, Gopalakrishnan R, Xiao G, Franceschi RT. Cooperative interactions between RUNX2 and homeodomain protein-binding sites are critical for the osteoblast-specific expression of the bone sialoprotein gene. *The Journal of Biological Chemistry.* 2005;280(35):30845–55. PMID: 16000302. Available from: [10.1074/jbc.M503942200](https://doi.org/10.1074/jbc.M503942200).
74. Bouleftour W, Juignet L, Bouet G, Granito RN, Vanden-Bossche A, Laroche N. The role of the SIBLING, Bone Sialoprotein in skeletal biology - Contribution of mouse experimental genetics. *Matrix Biology.* 2016;52-54(52):60–77. PMID: 26763578. Available from: [10.1016/j.matbio.2015.12.011](https://doi.org/10.1016/j.matbio.2015.12.011).
75. Jiménez MJ, Balbín M, López JM, Alvarez J, Komori T, López-Otin C. Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation. *Molecular and Cellular Biology.* 1999;19(6):4431–42. PMID: 10330183. Available from: [10.1128/MCB.19.6.4431](https://doi.org/10.1128/MCB.19.6.4431).
76. Wang X, Manner PA, Horner A, Shum L, Tuan RS, Nuckolls GH. Regulation of MMP-13 expression in osteoarthritic cartilage. *Osteoarthritis and Cartilage.* 2004;12(12):963–73. PMID: 15564063. Available from: [10.1016/j.joca.2004.08.008](https://doi.org/10.1016/j.joca.2004.08.008).
77. Paiva KB, Granjeiro JM. Bone tissue remodeling and development: focus on matrix metalloproteinase functions. *Archives of Biochemistry and Biophysics.* 2014;561:74–87. PMID: 25157440. Available from: [10.1016/j.abb.2014.07.034](https://doi.org/10.1016/j.abb.2014.07.034).
78. Lin PI, Tai YT, Chan WP, Lin YL, Liao MH, Chen RM. Estrogen/ER α signaling axis participates in osteoblast maturation via upregulating chromosomal and mitochondrial complex gene expressions. *Oncotarget.* 2017;9(1):1169–86. PMID: 29416685. Available from: [10.18632/oncotarget.23453](https://doi.org/10.18632/oncotarget.23453).
79. Lorenzo J. The many ways of osteoclast activation. *The Journal of Clinical Investigation.* 2017;127(7):2530–2. PMID: 28530641. Available from: [10.1172/JCI94606](https://doi.org/10.1172/JCI94606).
80. Park JH, Lee NK, Lee SY. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. *Molecules and Cells.* 2017;40(10):706–13. PMID: 29047262.
81. Matsuo K, Ray N. Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. *The Keio Journal of Medicine.* 2004;53(2):78–84. PMID: 15247511. Available from: [10.2302/kjm.53.78](https://doi.org/10.2302/kjm.53.78).
82. Mamun MA, Islam K, Alam M, Khatun A, Alam MM, Al-Bari M, et al. Flavonoids isolated from *Tridax procumbens* (TPF) inhibit osteoclasts differentiation and bone resorption. *Biological Research.* 2015;48(1):1–7. Available from: [10.1186/s40659-015-0043-6](https://doi.org/10.1186/s40659-015-0043-6).
83. Chiu YH, Ritchlin CT. DC-STAMP: A Key Regulator in Osteoclast Differentiation. *Journal of Cellular Physiology.* 2016;231(11):2402–7. PMID: 27018136. Available from: [10.1002/jcp.25389](https://doi.org/10.1002/jcp.25389).
84. Borciani G, Montalbano G, Baldini N, Cerqueni G, Vitale-Brovarene C, Ciapetti G. Co-culture systems of osteoblasts and

- osteoclasts: simulating in vitro bone remodeling in regenerative approaches. *Acta Biomaterialia*. 2020;108:22–45. PMID: 32251782. Available from: [10.1016/j.actbio.2020.03.043](https://doi.org/10.1016/j.actbio.2020.03.043).
85. Miki Y, Ono K, Hata S, Suzuki T, Kumamoto H, Sasano H. The advantages of co-culture over mono cell culture in simulating in vivo environment. *The Journal of steroid biochemistry and molecular biology*. 2012;131(3-5):68–75. Available from: [10.1016/j.jsbmb.2011.12.004](https://doi.org/10.1016/j.jsbmb.2011.12.004).
86. Kook YM, Jeong Y, Lee K, Koh WG. Design of biomimetic cellular scaffolds for co-culture system and their application. *Journal of Tissue Engineering*. 2017;8:2041731417724640. PMID: 29081966. Available from: [10.1177/2041731417724640](https://doi.org/10.1177/2041731417724640).
87. Li JY, Liu L, Wan ZM, Hao QX, Li RX, Guo Y. A novel co-culture system for interaction of mouse osteoblasts and osteoclasts. *Chinese Journal of Tissue Engineering Research*. 2013;17(15):2693.